Almirall Prodesfarma S.A., Forest Laboratories deal

Almirall granted FRX U.S. rights to LAS34273, an inhalable long-acting muscarinic receptor antagonist that has completed Phase II testing for chronic obstructive pulmonary disease (COPD). Phase III ...